July 2026 Research Update

Across two population-based studies, Behcet's disease was uncommon, but the estimated number of people living with it varied by region and by how cases were counted (health record coding versus identified patients in a defined area). Both studies also pointed to delays between early symptoms and a recorded diagnosis, which can affect how common the disease appears in data. [1] [2]

In England, linked primary and hospital records from 2001 to 2021 estimated an incidence rate of 0.75 per 100,000 person-years, and prevalence increased from 8.62 to 19.80 per 100,000 over the study period. This same dataset showed that certain features were much more common in people coded as having Behcet's syndrome than in matched controls, including genital ulceration, uveitis (eye inflammation), and oral ulceration. [1]

In Goiania and its metropolitan area in Brazil, 73 diagnosed patients were identified in 2022, and prevalence was estimated at 4.52 per 100,000 in Goiania and 3.27 per 100,000 in greater Goiania. The study also reported a 10-year incidence range of 0.14 to 0.45 per 100,000 per year (depending on area and year). In this group, the median time from symptom onset to diagnosis was 3.0 years. [2]

Both studies provided examples of diagnostic timing gaps: in England, the median time from the first genital ulceration code to a Behcet's syndrome diagnosis was 240 days, while the Brazilian regional study reported a longer delay from first symptoms to diagnosis. These time gaps matter because some people may have symptoms for a while before the condition is formally recognized in medical records. [1] [2]

For patients and caregivers, these studies mainly provide background context: Behcet's disease appears uncommon in the general population, but estimates can differ across countries and regions and can shift over time depending on how healthcare data are collected. The work also shows that delays between early symptoms (such as mouth or genital ulcers, or eye inflammation) and a recorded diagnosis are common, which can influence reported rates. What remains uncertain is how much of the difference between regions reflects true differences versus differences in recognition, referral patterns, and the limits of using diagnostic coding or identified clinic patients to count cases. [1] [2]

This month, studies looked at whether Behcet's disease (BD) or BD-related eye inflammation can be supported by measurable signals in blood or on ultrasound. Overall, results suggest certain blood proteins move up or down in BD, and a specific ultrasound measurement of a large leg vein was higher in BD-related uveitis, but all results come from single-center, cross-sectional or retrospective work and are not yet definitive. [3] [4] [5] [6]

In a retrospective clinic study of people with uveitis, those with Behcet's uveitis had thicker walls of the common femoral vein (a large vein in the upper leg) on both sides compared with people with other types of uveitis. This difference stayed after statistical adjustment, suggesting the ultrasound measurement could be a supportive clue when the question is "Behcet's uveitis or something else," but it was measured by a single radiologist and may not generalize to all uveitis populations. [3]

In a serum proteomics study focused on mouth ulcers, three blood proteins (ANXA2, ENO1, and S100A7) were higher in idiopathic recurrent aphthous stomatitis than in BD, and each showed strong ability to separate the two groups in the study's validation cohort. This points to a potential future blood test to help distinguish recurrent "simple" mouth ulcers from BD in research settings, but the cohorts were small and from a single center. [4]

Two case-control studies compared BD to healthy controls using blood tests. One found higher angiopoietin-1 and angiopoietin-2 in BD, with angiopoietin-2 rising along with common inflammation tests, and angiopoietin-1 lower among those with genital ulcers. [5] Another found lower DNASE1L3 in BD, which also moved in the opposite direction of inflammation tests and showed high accuracy in that single dataset, but it was presented as preliminary and needing larger validation. [6]

For patients and caregivers, these results mainly add background about possible future tools that might support diagnosis or help separate BD from look-alike conditions (such as other uveitis causes or recurrent mouth ulcers without BD). Right now, the studies do not establish a single blood test or ultrasound measurement as a standalone way to diagnose BD, because they were small, single-center, and mostly one-time snapshots; it remains uncertain how well these markers perform across different ages, ethnic groups, disease stages, and real-world clinics. [3] [4] [5] [6]

Across this group of studies, vascular and heart complications in Behcet's disease showed up in several ways: inflammation and damage in medium and large arteries, aneurysms (bulging blood vessels) including in the lungs, and clots inside the heart. The overall pattern was that these complications can be serious and sometimes life-threatening, and many reports emphasized coordinated care across specialties and repeated imaging to understand what is happening over time. [7] [8] [9] [10]

In a retrospective cohort of 76 children, those with arterial involvement (19 children) had more signs of widespread inflammation and more severe outcomes than those without arterial involvement. This group had higher rates of stroke events, heart complications, and death, and artery changes included wall thickening, widening, and narrowing, with a report of left main coronary artery dilation. [7]

A multicenter Turkish case series of 65 people with nonpulmonary arterial involvement reported that the aorta and femoral artery were the most commonly affected vessels, and aneurysms were more common than thrombosis. Relapse (a new arterial event) occurred in 10 patients, and deaths were most often in people who also had arterial and heart involvement. [8]

Pulmonary (lung) artery problems were uncommon in one pulmonology-center cohort of 279 adults, but they were clinically important when present, including pulmonary artery aneurysm and pulmonary artery thrombosis. In the available data, anticoagulant-related complications were limited, with one report of coughing up blood and one report of heavy menstrual bleeding. [9]

A systematic review of 218 reported cases of intracardiac thrombosis (a clot inside the heart) described that it often affected young men and was sometimes the first sign of Behcet's disease. Across these reports, combinations of anti-inflammatory and immune-suppressing medicines together with anticoagulants were linked with clot resolution in many cases, while surgery was linked with higher recurrence and higher death rates in the reported cases. [10]

Several small reports described complex, individualized management for high-risk situations. These included device occlusion of a giant pulmonary artery aneurysm in a 12-year-old, and stabilization of a young man with massive coughing up blood from multiple pulmonary artery aneurysms and thrombosis after immune-suppressing treatment followed by embolisation. [11] [12]

Other case reports highlighted how bleeding from lung artery aneurysms can recur and may be managed with immune-suppressing medicines and planned imaging follow-up, and how infected aortic stent grafts may require major surgery with long recovery and later complications. A small pediatric case series (5 girls) described improvement of arterial and intestinal lesions on follow-up imaging after glucocorticoids combined with immunosuppressants or anti-TNF therapy, with no severe adverse events reported in that series. [13] [14] [15]

Finally, individual cases illustrated that vascular inflammation and clotting problems can overlap with other inflammatory blood vessel conditions, and that diagnosing the exact cause can be challenging when symptoms involve the brain and large arteries. One case series focused on cardiac clots and embolic complications in systemic inflammatory diseases (including Behcet's disease) and stressed early recognition and multidisciplinary planning. [16] [17]

For patients and caregivers, these studies reinforce that Behcet's disease can affect blood vessels and the heart in multiple, very different ways, and that the most serious complications often involve large or medium arteries, the lung arteries, or clots inside the heart. Much of the evidence this month comes from retrospective studies and individual case reports, so it describes what happened in specific groups rather than proving what will happen for any one person. What remains uncertain includes which patients are most likely to develop each type of complication and which approaches work best in different real-world situations, especially for rare problems like lung artery aneurysms or intracardiac clots. [7] [8] [10]

Across a year-long cohort study and a separate single-patient report, adalimumab treatment was linked to calmer eye inflammation and better eye structure and function in Behcet disease-related uveitis, often alongside reduced steroid needs. These reports also highlight that infections and incomplete response can occur, and the strength of evidence is stronger for the cohort study than for the case report. [18] [19]

In a prospective study of 25 people with Behcet disease whose uveitis did not respond to standard immune-suppressing medicines, adalimumab over 12 months improved visual acuity and several signs of eye inflammation, including haze in the gel of the eye and inflammation of retinal blood vessels. The average daily steroid dose decreased during follow-up, and mouth and genital ulcers were controlled in most participants. Two people stopped adalimumab because of systemic infection, and one person switched to infliximab due to an inadequate response. [18]

A case report described a 29-year-old woman whose first eye sign of Behcet disease was an unusual inflammatory clump in the gel in front of the optic nerve, along with fluid under the central retina. After high-dose steroid treatment followed by adalimumab, the report noted improvement in vision-related function and regression of the infiltrate and retinal fluid on eye scans. Because this was one patient, it cannot show how often this happens or how well the same approach works for others. [19]

For patients and caregivers, this set of papers mainly adds real-world information about adalimumab for Behcet-related uveitis that has not responded well to other treatments, including the possibility of reducing steroid exposure and improving eye inflammation over about a year. It also underscores that serious infections can be a reason to stop treatment, and that some people may not respond enough and may need a different medicine. What remains uncertain here is how these results compare with other options or different patient groups, since the main evidence is a small single-group study plus one case report.

Two large epidemiology studies looked at who develops different types of uveitis and what other health conditions may be present. Together, they suggest that sex and age meaningfully shape uveitis populations, while links between diabetes and specific uveitis diagnoses may be less clear after accounting for age and sex. [20] [21]

A systematic review and meta-analysis of 19 studies reported that some uveitis causes were more common in females, while others were more common in males. In that analysis, Behcet disease-related uveitis showed a male predominance (risk ratio 0.52 for females compared with males). The authors noted that results came from specialist cohorts and may not represent every setting. [20]

In a Japanese single-center retrospective study of 3163 adults newly diagnosed with uveitis, diabetes was present in 5.3% overall and was more common in infectious uveitis than noninfectious uveitis before adjusting for other factors. After adjusting for age and sex, older age and male sex were the strongest correlates of diabetes, and differences by specific uveitis diagnosis were not statistically significant; Behcet disease had a diabetes prevalence of 1.8% in this cohort. The study cautioned that single-center design and referral patterns could affect how well these numbers generalize. [21]

This theme is mostly background context rather than information that changes treatment. It helps explain why clinic populations may look different by sex and age, and why other health conditions like diabetes may be more related to overall risk factors (such as being older or male) than to a specific uveitis label in some datasets. Uncertainty remains because the sex analysis drew from varied specialist cohorts, and the diabetes study was from one center in Japan and may not reflect other countries or care settings.

Across this month's papers, treatment evidence ranged from a small retrospective study to case reports and a mechanistic study with a short patient treatment component. The clearest clinical signal in intestinal Behcet disease was symptom and bowel-healing improvement reported with ustekinumab, while stem cell transplant approaches were described only in a few patients and showed mixed outcomes with important safety considerations. A separate translational study connected a specific immune pathway in Behcet disease to the effects of PDE4-inhibitor medicines, including short-term improvement in overall disease activity scores. [22] [23] [24] [25] [26]

In a retrospective cohort of 16 people with intestinal Behcet disease, ustekinumab was linked to high clinical response and remission rates over time, along with improvements seen on bowel scope exams and imaging. At 3 months, 14 of 16 had a clinical response and 11 of 16 were in clinical remission. Among five people using steroids at the start, all stopped steroids by 6 months, and 3 of 16 had side effects that were described as self-limiting with no treatment stops due to side effects. [22]

Two reports addressed stem cell transplantation in very severe, hard-to-treat situations, but they point in different directions. One case report described a 42-year-old woman with refractory perforating intestinal Behcet disease and aplastic anemia who had an allogeneic stem cell transplant from a matched sibling and had remission of both intestinal disease and bone marrow failure for about 12 months, with transient virus signal in blood but no graft-versus-host disease reported. [23]

By contrast, a two-patient case series of probable neuro-Behcet syndrome treated with autologous stem cell transplantation as rescue therapy reported no clinical benefit in either case. One patient died from infection nine months after transplant, and the other had ongoing disease activity with new brain and brainstem lesions and required a brain biopsy for diagnostic clarification. [24]

A translational study focused on why some immune cells may stay highly activated in Behcet disease and tested whether blocking PDE4 could calm that activation. The researchers found signs of NF-kB pathway activation and higher PDE4 expression in proinflammatory CD8 T cells from Behcet disease patients, and PDE4 inhibitors reduced activation and inflammatory signals in lab tests; in 12 treated patients, apremilast was linked to improvement in a clinical activity score over 12 weeks. This study helps explain a possible biological reason a PDE4 inhibitor might reduce inflammation, but it did not focus specifically on intestinal disease outcomes. [25]

One additional small case series described seven patients with severe Adamantiades-Behcet disease treated with pegylated interferon-alpha-2a, but the summary available here did not include response results or safety details. [26]

For patients with intestinal Behcet disease, the ustekinumab study adds real-world information suggesting many people improved and some had bowel healing on testing, with limited side effects reported in that small group, but it cannot prove how well it works compared with other options. The stem cell transplant papers are best viewed as background about rare, extreme situations: one person with both bowel disease and bone marrow failure improved after a matched-donor transplant, while two people with neuro-Behcet did not improve after autologous transplant and one died from infection, highlighting uncertainty and potential risks. The PDE4 inhibitor study mainly helps explain disease biology and reports short-term improvement in overall activity scores, but it does not answer which severe or intestinal subgroups benefit most or how durable effects are.

Across this group of studies, mental health symptoms showed up in two main ways: common anxiety and depression reported by many people with Behcet's disease, and less common but sometimes severe psychiatric symptoms when the nervous system is involved. Overall, higher disease activity and inflammation markers tended to go along with worse psychological well-being, but these studies cannot prove one causes the other. [27] [28]

In a cross-sectional study of 192 Arabic-speaking adults with Behcet's disease, 53.1% screened positive for anxiety and 38.5% for depression on a standard questionnaire. Higher anxiety and depression scores were linked to lower health-related quality of life across all areas measured, and higher anxiety was also linked to higher disease activity and higher erythrocyte sedimentation rate (a blood marker of inflammation). [27]

A case report plus a systematic review (34 published neuro-psycho Behcet cases) described a wide range of psychiatric symptoms, including affective symptoms (such as mania or depression), psychotic symptoms, and behavior changes. Brain imaging in these reports often showed inflammation in brain tissue (parenchymal lesions), and care in the published cases typically combined immune-targeting treatment for Behcet's disease with psychiatric medications. [28]

For patients and caregivers, this research mainly helps set expectations about how often mood symptoms are reported in Behcet's disease and how strongly they can relate to daily functioning and perceived health. The survey results reflect a specific population and a single point in time, while the neuro-psychiatric paper is based on case reports that may overrepresent unusual or severe presentations. What remains uncertain is how often psychiatric symptoms are directly driven by nervous system inflammation versus other factors (such as stress, pain, sleep disruption, or medication effects), because these studies were not designed to determine cause and effect. [27] [28]

These studies point to a pattern that nervous system involvement in Behcet's disease may cluster in families and may also relate to differences in immune-system genes. The evidence here is observational, meaning it can show links but cannot confirm why these links exist. [29] [30]

In a retrospective study of 891 people with Behcet's disease, neurological involvement was reported more often in those who had an affected sibling than in those without a sibling history. After adjusting for other factors, having an affected sibling was linked to about three times higher odds of neurological involvement. [29]

In a small cross-sectional study (42 patients and 20 healthy controls), nerve conduction testing suggested peripheral nerve involvement in the evaluated Behcet group, while about half reported neuropathy symptoms. The study also found that one CCL21 gene variant (rs2492358) differed between patients and controls, and another (rs951005) was linked to higher disease activity, suggesting a possible connection between inflammation pathways and peripheral nerve changes. [30]

For patients, this evidence is mostly background research about why nerve problems may develop in some people with Behcet's disease and not others. The family-history study suggests shared inherited factors may matter for nervous system involvement, but it does not explain which genes or environmental factors drive this. The gene study is exploratory and small, so it cannot yet tell whether testing for these gene variants will be useful in routine care or whether the findings apply to all patient groups. [29] [30]

Across the pediatric literature, Behcet's disease in children most often starts and stays noticeable through mucocutaneous symptoms (mouth and genital sores and skin changes), while involvement of joints, eyes, the nervous system, the gut, and blood vessels is also reported and varies a lot between studies. Overall, the papers point to real differences in how the disease shows up from child to child, and to variation in how it is followed and treated, which makes it harder to compare outcomes across clinics. [31]

In a systematic review of 52 observational studies (2,929 children diagnosed before age 16), mucocutaneous involvement was reported in nearly all children (97.8%) and was the first feature in most (80.9%). Other reported involvement included musculoskeletal (36%), ocular (35%), neurological (17.9%), gastrointestinal (20%), and vascular (15.4%), with substantial differences across cohorts. [31]

One case report described a 12-year-old boy whose main issues were recurrent oral and scrotal ulcers, papulopustular skin lesions, and joint pains, with a positive pathergy test. Symptoms improved with topical therapy and colchicine, and eye and gastrointestinal assessments at that time did not show major-organ involvement. [32]

A proof-of-concept study tested whether a machine learning approach could recognize flares using daily diary entries, but it used fully simulated (not real) pediatric patient data. The best-performing models mainly relied on oral ulcers, joint pain, and fever, and the authors noted these features were built into the flare-labeling rule and must be validated in real children before clinical use. [33]

For families, these papers reinforce that day-to-day symptoms like mouth sores, skin lesions, fever, and joint pain often play a big role in pediatric Behcet's disease, but they do not capture the full picture because eye, gut, nerve, or blood-vessel problems can occur and may differ across children. The strongest evidence here is a large review showing how common different organ involvements are, while the diary-based flare work is background research that is not ready for real-world care because it was tested only on synthetic data. What remains uncertain is how best to standardize symptom tracking and monitoring across clinics so children can be compared more consistently over time. [31] [32] [33]

Several non-pediatric papers still speak to long-term daily management and life stages that some patients diagnosed in childhood will reach, including staying on medications, pregnancy, and rare organ complications. Together, they suggest that practical care challenges (like adherence) and risk patterns can differ by age and situation, while biology studies are mapping immune and genetic signals that may relate to different organ-involvement types. [34] [35] [36] [37] [38]

In a cross-sectional study of 125 adults, most reported intermediate or high medication adherence, but about one-fifth had low adherence (21.6%). Younger age was linked to lower adherence, while sex, disease duration, disease activity scores, and treatment class did not show clear links in this dataset. [34]

A nationwide Spanish analysis of pregnancy-related hospitalizations (2016 to 2022) reported that Behcet disease was mainly linked to increased maternal thrombosis, with an odds ratio of 9.31 compared with pregnancies without autoimmune disease. This study compared many autoimmune diseases and showed that risk patterns differed by diagnosis rather than being the same across conditions. [35]

Two adult case reports highlight that Behcet disease can sometimes present with very severe mucocutaneous disease or with uncommon organ problems. One 36-year-old man with severe necrotic genital ulcers and widespread mucocutaneous involvement achieved remission after corticosteroids plus colchicine, with no recurrence at five months, and histology supported inflammation of blood vessels. [39]

Another 36-year-old man with an 18-year history developed progressive epiglottic deformity and acute swelling above the vocal cords that caused shortness of breath and swallowing difficulty; after microlaryngoscopic CO2 laser surgery, breathing symptoms resolved without recurrence at three months. As single-patient reports, these examples may not apply to most people with Behcet disease. [40]

Biology studies using blood cells suggest that Behcet disease involves shifts in immune-cell programs that can differ by disease activity and by organ pattern. One single-cell study reported expanded monocyte subsets with interferon-related and stress-response programs during active disease, with changes reversing in remission, and it reported different signatures for vascular versus ocular phenotypes. [36]

A small pilot study in vasculo-Behcet disease performed whole exome sequencing in one of five patients and prioritized nine candidate genes linked to vascular pathways, but the authors emphasized this is exploratory because sequencing was done in only one person. Another integrative study combining human data and a mouse model identified BTN3A2 as a protective factor shared between Behcet disease and inflammatory bowel disease, and linked lower BTN3A2 expression to changes in a specific CD4 T cell population and to connections between eye and gut inflammation signals; the authors noted limitations such as reliance on blood measures and challenges translating primate-specific biology. [37] [38]

For patients and caregivers thinking longer-term, these studies add context about life stages and complications that may come up later, rather than changing pediatric care now. The adherence and pregnancy data are more directly relevant to real-world decision-making because they come from patient and population datasets, while the case reports mainly illustrate that rare severe presentations can occur. The immune and genetic studies are mostly background research: they help explain why Behcet disease may look different across people (for example, eye versus blood-vessel patterns), but they do not yet translate into specific day-to-day management steps, and many results need confirmation in larger and more diverse groups. [34] [35] [39] [40] [36] [37] [38]